Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment

Histopathology
Lianne KoensDaphne de Jong

Abstract

CD30 immunohistochemistry (IHC) in malignant lymphoma is used for selection of patients in clinical trials using brentuximab vedotin, an antibody drug-conjugate targeting the CD30 molecule. For reliable implementation in daily practice and meaningful selection of patients for clinical trials, information on technical variation and interobserver reproducibility of CD30 immunohistochemistry (IHC) staining is required. We conducted a three-round reproducibility assessment of CD30 scoring for categorised frequency and intensity, including a technical validation, a 'live polling' pre- and post-instruction scoring round and a web-based round including individual scoring with additional IHC information to mimic daily diagnostic practice. Agreement in all three scoring rounds was poor to fair (κ = 0.12-0.35 for CD30-positive tumour cell percentage and κ = 0.16-0.41 for staining intensity), even when allowing for one category of freedom in percentage of tumour cell positivity (κ = 0.30-0.61). The first round with CD30 staining performed in five independent laboratories showed objective differences in staining intensity. In the second round, approximately half the pathologists changed their opinion on CD30 frequency after a discussion on...Continue Reading

References

Jun 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G NadaliJ P Greer
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G NadaliA Vassanelli
Nov 25, 1998·Seminars in Immunology·R Horie, T Watanabe
Jul 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezRobert B Jenkins
Mar 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daphne de JongUNKNOWN Lunenburg Lymphoma Biomarker Consortium
Jan 29, 2011·Blood·Dennis D WeisenburgerUNKNOWN International Peripheral T-cell Lymphoma Project
Oct 12, 2011·Current Opinion in Oncology·Anas Younes
May 30, 2013·Haematologica·Elena SabattiniStefano A Pileri
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Aug 20, 2014·British Journal of Haematology·Graham W SlackRandy D Gascoyne
May 21, 2015·American Society of Clinical Oncology Educational Book·David W Scott
Nov 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adil I DaudOmid Hamid

❮ Previous
Next ❯

Citations

Jul 7, 2019·The British Journal of Dermatology·G DobosA de Masson
Aug 18, 2020·Cytometry. Part B, Clinical Cytometry·Agathe DebliquisBernard Drenou
Jan 11, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Angeles Alvarez SecordAndrew B Nixon

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.